Valneva SE VALN
NASDAQ VALN
$7.00 -0.06 (-0.85%)
As of: Sep 4, 2026 · 1:38 PM EDT

Valneva SE (VALN) Net Income towards Common Stockholders (2021 - 2026)

Valneva SE (VALN) posted Net Income towards Common Stockholders of -$27.7 million for Q1 2026, up 52.41% sequentially from -$58.3 million in Q4 2025, and down 342.51% YoY from $11.4 million in Q1 2025.

Analysis

Valneva SE (VALN) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends

Valneva SE has reported Net Income towards Common Stockholders for 6 years, with the latest figure at -$27.7 million in Q1 2026.

  • Quarterly Net Income towards Common Stockholders fell 342.51% year-over-year to -$27.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$154.9 million (down 135.6% YoY) and the FY2025 annual result came in at -$134.1 million, down 1029.61% from the prior year.
  • Net Income towards Common Stockholders grew to -$27.7 million in Q1 2026 per VALN's latest filing, from -$58.3 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $94.1 million in Q3 2022 and troughed at -$156.3 million in Q2 2022.
  • A 5-year average of -$22.5 million and a median of -$24.1 million in 2024 frame the typical range for Net Income towards Common Stockholders.
  • The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders surged 516.53% in 2024, then sank 379.79% in 2025.
  • Over 5 years, Net Income towards Common Stockholders stood at -$57.5 million in 2022, then jumped by 53.39% to -$26.8 million in 2023, then surged by 54.66% to -$12.1 million in 2024, then tumbled by 379.79% to -$58.3 million in 2025, then soared by 52.41% to -$27.7 million in 2026.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$27.7 million, -$58.3 million, and -$56.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 139.31 Bn 131.46 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.65 Bn 77.66 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn 472.00 Mn
4 Moderna 57.94 Bn 52.80 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn - -644.37 Mn
6 BeOne Medicines 39.96 Bn 34.86 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.16 Bn 31.85 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn - 81.49 Mn
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn -13.27 Mn
10 Valneva SE 581.90 Mn 440.64 Mn 1.86 Mn 0.20
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 0.20
Mar 31, 2026 0.21
Dec 31, 2025 0.34
Sep 30, 2025 0.30
Jun 30, 2025 0.08
Mar 31, 2025 0.06
Dec 31, 2024 -0.11
Sep 30, 2024 -0.08
Jun 30, 2024 -0.18
Mar 31, 2024 0.46
Dec 31, 2023 0.25
Sep 30, 2023 0.27
Jun 30, 2023 0.13
Mar 31, 2023 0.14
Dec 31, 2022 0.33
Sep 30, 2022 151.65 Mn
Jun 30, 2022 -151.43 Mn
Mar 31, 2022 -28.10 Mn
Dec 31, 2021 201.46 Mn
Sep 30, 2021 -185.83 Mn